Aldeyra Therapeutics, Inc.
ALDX
$1.71
-$0.05-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -51.90% | -8.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.81% | -16.66% | |||
| Operating Income | 46.81% | 16.66% | |||
| Income Before Tax | 46.57% | 15.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 46.57% | 15.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.57% | 15.96% | |||
| EBIT | 46.81% | 16.66% | |||
| EBITDA | 47.29% | 16.81% | |||
| EPS Basic | 46.74% | 16.03% | |||
| Normalized Basic EPS | 46.65% | 16.02% | |||
| EPS Diluted | 46.74% | 16.03% | |||
| Normalized Diluted EPS | 46.65% | 16.02% | |||
| Average Basic Shares Outstanding | 0.26% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||